After gains of 15.6% this afternoon, Penumbra shares are now trading at $209.78. Read below for the essential facts about this stock:
-
Penumbra has logged a 8.0% 52 week change, compared to 12.0% for the S&P 500
-
PEN has an average analyst rating of buy and is -31.01% away from its mean target price of $304.08 per share
-
Its trailing earnings per share (EPS) is $1.05, which brings its trailing Price to Earnings (P/E) ratio to 199.8. The Health Care sector's average P/E ratio is 24.45
-
The company's forward earnings per share (EPS) is $2.79 and its forward P/E ratio is 75.2
-
The company has a Price to Book (P/B) ratio of 7.33 in contrast to the Health Care sector's average P/B ratio is 4.16
-
The company's free cash flow for the last fiscal year was $510000 and the average free cash flow growth rate is -45.4%
-
Penumbra's revenues have an average growth rate of 13.2% with operating expenses growing at None%. The company's current operating margins stand at 4.1%